| 证券代码 | BNTCW.O |
| 证券名称 | Benitec Biopharma Ltd Wt |
| 证券类型 | 美国权证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2015-08-18 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | - |
| 公司名称 | Benitec Biopharma Limited |
| 注册地址 | 澳大利亚 |
| 办公地址 | 99 Mount Street, Suite 1201, North Sydney, New South Wales, Australia |
| 成立日期 | 1995 |
| 董事会主席 | - |
| 公司属地 | Australia 澳大利亚 |
| 公司网址 | www.benitec.com |
| 电话 | +61 (2) 9555-6986 |
| 传真 | +61 (2) 9818-2238 |
| 公司简介 | Benitec Biopharma Limited is a clinical-stage biotechnology company focused on the development of novel genetic medicines. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including oculopharyngeal muscular dystrophy (OPMD), squamous cell carcinoma of the head & neck (SCCHN), ophthalmolgic disorders such as wet age-related macular degeneration (AMD), and chronic hepatitis B. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain, cancer immunotherapy and retinitis pigmentosa. |